- Yesterday it was Biogen (BIIB). Today it's AstraZeneca (AZN). Isis Pharmaceuticals (ISIS) earns a $15M milestone payment from AZN by virtue of its initiation of a Phase 1 clinical trial for ISIS-ARrx, an antisense drug for the treatment of prostate cancer that works by inhibiting the production of the androgen receptor. Isis has now earned $57M to date on its development and is eligible for additional milestone payments as the product progresses through clinical trials.
at Zacks.com (Nov 18, 2014)